<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006664</article-id><article-id pub-id-type="pmc">PMC11860294</article-id><article-id pub-id-type="doi">10.3390/vaccines13020117</article-id><article-id pub-id-type="publisher-id">vaccines-13-00117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6314-0965</contrib-id><name><surname>Gwin</surname><given-names>William R.</given-names><suffix>III</suffix></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00117" ref-type="aff">2</xref><xref rid="c1-vaccines-13-00117" ref-type="corresp">*</xref><xref rid="fn1-vaccines-13-00117" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Salazar</surname><given-names>Lupe G.</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00117" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>James Y.</given-names></name><xref rid="af2-vaccines-13-00117" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Higgins</surname><given-names>Doreen</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1710-5637</contrib-id><name><surname>Coveler</surname><given-names>Andrew L.</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00117" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Childs</surname><given-names>Jennifer S.</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Blancas</surname><given-names>Rosie</given-names></name><xref rid="af3-vaccines-13-00117" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7661-0855</contrib-id><name><surname>Dang</surname><given-names>Yushe</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Reichow</surname><given-names>Jessica</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8492-6705</contrib-id><name><surname>Slota</surname><given-names>Meredith</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Hailing</given-names></name><xref rid="af4-vaccines-13-00117" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7653-4648</contrib-id><name><surname>Disis</surname><given-names>Mary L.</given-names></name><xref rid="af1-vaccines-13-00117" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00117" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00117"><label>1</label>Cancer Vaccine Institute, University of Washington, 850 Republican Street, Box 358050, Seattle, WA 98195, USA; <email>lsalazar@uw.edu</email> (L.G.S.); <email>acoveler@uw.edu</email> (A.L.C.); <email>childj@medicine.washington.edu</email> (J.S.C.); <email>ydang@medicine.washington.edu</email> (Y.D.); </aff><aff id="af2-vaccines-13-00117"><label>2</label>Fred Hutchinson Cancer Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA; <email>jdai@fredhutch.org</email></aff><aff id="af3-vaccines-13-00117"><label>3</label>Breastlink Medical Group, 230 S Main St, #100, Orange County, CA 92868, USA</aff><aff id="af4-vaccines-13-00117"><label>4</label>Seattle Genetics (Pfizer), 21823 30th DR SE, Bothell, WA 98021, USA</aff><author-notes><corresp id="c1-vaccines-13-00117"><label>*</label>Correspondence: <email>wrgwin@uw.edu</email>; Tel.: +1-206-543-8557; Fax: +1-206-685-3128</corresp><fn id="fn1-vaccines-13-00117"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>117</elocation-id><history><date date-type="received"><day>19</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>05</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives</bold>: Regulatory T cells (Treg) suppress immunity in the tumor microenvironment, are linked to poor prognosis across breast cancer subtypes, and suppress the cytolytic function of cytotoxic CD8+ T cells. Denileukin diftitox, a diphtheria toxin (DT)/IL-2 fusion protein, targets and depletes Tregs. This Phase II study aimed to assess the safety of denileukin diftitox and its effect on Tregs and tumor growth in patients with advanced breast cancer. <bold>Methods</bold>: This single-arm Phase II study of denileukin diftitox enrolled patients with refractory stage IV breast cancer. Patients received denileukin diftitox 18 mcg/kg/day IV for Days 1&#x02013;5 every 21 days for up to six cycles. Toxicity was assessed using CTCAE v3.0 and tumor response was evaluated per RECIST criteria. Blood samples were collected to analyze Tregs by flow cytometry and anti-DT antibodies by ELISA. <bold>Results</bold>: Fifteen patients with stage IV breast cancer were enrolled. Four patients completed all planned denileukin diftitox infusions and achieved stable disease (27%, 95% CI [0.08, 0.55]). Two patients (13%) discontinued due to toxicity, and nine patients (60%) discontinued due to progressive disease. Eleven patients experienced at least one grade 3 or 4 adverse event. Although there was a general reduction in peripheral blood Tregs, the difference in CD4+CD25+FOXP3+ Tregs levels post-treatment was not statistically significant (<italic toggle="yes">p</italic> = 0.10). Six patients (40%) achieved <inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>25% reductions in Tregs. A significant increase in anti-DT IgG antibodies was observed post-treatment (<italic toggle="yes">p</italic> &#x0003c; 0.005). <bold>Conclusions</bold>: Denileukin diftitox demonstrated moderate toxicity in this advanced breast cancer cohort. Denileukin diftitox modulated regulatory T cells. However, the majority of patients experienced disease progression in the study.</p></abstract><kwd-group><kwd>denileukin diftitox</kwd><kwd>regulatory T-cells</kwd><kwd>breast cancer</kwd><kwd>immunity</kwd><kwd>tumor microenvironment</kwd></kwd-group><funding-group><award-group><funding-source>National Institutes of Health (NIH) R21</funding-source><award-id>5R21CA114958-2</award-id></award-group><award-group><funding-source>Salazar PI</funding-source></award-group><award-group><funding-source>Komen Leadership Award</funding-source></award-group><award-group><funding-source>American Cancer Society Clinical Professorship</funding-source></award-group><award-group><funding-source>Athena Distinguished Professor of Breast Cancer Research</funding-source></award-group><funding-statement>This research was funded by National Institutes of Health (NIH) R21 (5R21CA114958-2), Salazar PI, funded the conduct of this study. Dr. Disis was supported by the Komen Leadership Award, American Cancer Society Clinical Professorship and the Athena Distinguished Professor of Breast Cancer Research.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00117"><title>1. Introduction</title><p>The role of the immune system in breast cancer has gained substantial recognition in recent years [<xref rid="B1-vaccines-13-00117" ref-type="bibr">1</xref>]. Traditionally, the presence of tumor-infiltrating lymphocytes (TILs) has been used as an indicator of immune interaction with tumors, with TILs correlating with improved overall survival, particularly in basal-like and HER-2 enriched subtypes [<xref rid="B2-vaccines-13-00117" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00117" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00117" ref-type="bibr">4</xref>]. Recent evidence suggests that the quantity and functionality of cancer-specific immune responses, both local and systemic, are crucial for prognosis [<xref rid="B5-vaccines-13-00117" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00117" ref-type="bibr">6</xref>]. Specifically, CD8+ cytotoxic T cells have been linked to better survival outcomes, independent of tumor size, stage, or HER2 status [<xref rid="B7-vaccines-13-00117" ref-type="bibr">7</xref>]. Conversely, regulatory T cells (Treg), found in both the tumor microenvironment and peripheral blood, are associated with poor prognosis across all breast cancer subtypes, with high Treg infiltration reported in 67% of HER2-enriched and 70% of basal-like breast cancers [<xref rid="B8-vaccines-13-00117" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00117" ref-type="bibr">9</xref>].</p><p>The presence of CD4+ Th1 T cells and their secretion of IFN-gamma are critical for the activation and proliferation of CD8+ T cells, promoting a Type I immune environment that facilitates direct tumor cell lysis [<xref rid="B10-vaccines-13-00117" ref-type="bibr">10</xref>]. In contrast, a Type 2 immune environment, characterized by CD4+ (Th2) T cells and CD4+CD25+FOXP3+ Tregs, secretes cytokines that inhibit CD8+ T cell activation. The presence of CD25 + FOXP3+ Tregs is linked to decreased relapse-free survival and poorer clinical outcomes in breast cancer [<xref rid="B11-vaccines-13-00117" ref-type="bibr">11</xref>]. Therefore, strategies to enhance Type 1 immunity while suppressing Type 2 responses are essential for improving anti-tumor efficacy.</p><p>Denileukin diftitox (DD) is a fusion protein composed of diphtheria toxin with interleukin-2 (IL-2) that is specifically designed to target cells expressing the IL-2 receptor (IL-2R). Upon binding to IL-2R, DD is internalized through receptor-mediated endocytosis, selectively targeting cells that express the high-affinity IL-2R, which includes CD25 (IL-2R&#x003b1;), CD122 (IL-2R&#x003b2;), and CD132 (&#x003b3;c)] [<xref rid="B12-vaccines-13-00117" ref-type="bibr">12</xref>]. Tregs constitutively express three IL-2R subunits, making them a target for DD. After being withdrawn from the market in 2014, a re-engineered formulation of denileukin diftitox with enhanced purity and bioactivity (denileukin diftitox-cxdl) received FDA approval in August 2024 for cutaneous T cell lymphoma (CTCL) expressing IL-2Ra (CD25). This approval was based on results from a Phase III trial that demonstrated an objective response rate of 36.2% (95% confidence interval [CI] = 25.0%&#x02013;48.7%), including a complete response of 8.7% [<xref rid="B13-vaccines-13-00117" ref-type="bibr">13</xref>]. </p><p>Treatment with DD for other tumor types has also shown reductions in regulatory T cells in ovarian cancer (significant reduction in mean Treg levels, <italic toggle="yes">p</italic> = 0.025) [<xref rid="B14-vaccines-13-00117" ref-type="bibr">14</xref>], melanoma (Treg reductions in all treated patients) [<xref rid="B15-vaccines-13-00117" ref-type="bibr">15</xref>], and renal cell carcinoma (26&#x02013;76% reduction in Tregs) [<xref rid="B16-vaccines-13-00117" ref-type="bibr">16</xref>]. These studies reported adverse events consistent with the known side effect profile of DD, with the most common grade 3 or 4 adverse event being vascular leak syndrome.</p><p>Our group has previously demonstrated in pre-clinical breast cancer models that DD reduces Tregs in the tumor microenvironment (<italic toggle="yes">p</italic> &#x0003c; 0.03) and is associated with immune-mediated tumor rejection [<xref rid="B17-vaccines-13-00117" ref-type="bibr">17</xref>]. Building on these findings, a Phase II study was conducted to assess the safety and efficacy of DD in targeting breast cancer cells, reducing Tregs, and inhibiting tumor growth in patients with advanced refractory breast cancer.</p></sec><sec id="sec2-vaccines-13-00117"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00117"><title>2.1. Patient Population</title><p>After providing informed consent, patients with stage IV breast cancer were enrolled in this trial from October 2006 to August 2009 (NCT00425672). The study was approved by the University of Washington Cancer Consortium institutional review board. Eligibility criteria included progressive or relapsed disease, measurable disease, and Eastern Cooperative Oncology Group (ECOG) performance status of &#x02264;2. Concurrent use of endocrine and bisphosphonate therapy was allowed. Enrolled patients received intravenous (IV) denileukin diftitox (ONTAK) 18 mcg/kg/day on Days 1&#x02013;5 every 21 days for a total of 6 cycles. Dose reductions were allowed for toxicity. Tumor response was evaluated per RECIST. Immunologic monitoring of the peripheral blood Treg population and endogenous tumor antigen-specific T cell immunity occurred at baseline and after cycles 2, 4, and 6.</p></sec><sec id="sec2dot2-vaccines-13-00117"><title>2.2. Study Design</title><p>In this Phase II, non-randomized, single-arm clinical trial, the primary objectives were to evaluate (1) the safety of denileukin diftitox (ONTAK) infusion and (2) the effect of denileukin diftitox (ONTAK) administration on peripheral blood Tregs. Toxicity grading was evaluated according to the CTEP Common Terminology Criteria for Adverse Events (CTCAE) v3.0. The efficacy of denileukin diftitox in depleting Tregs was defined as a decrease in peripheral blood Tregs (CD4+CD25+FOXP3+) by 25% with denileukin diftitox treatment. To evaluate the anti-tumor response of denileukin diftitox, imaging studies were performed to assess target lesions at baseline and after cycles 2, 4, and 6 of treatment. Responses were categorized into four groups: (1) complete response (CR), (2) partial response (PR), (3) progressive disease (PD), and (4) stable disease (SD). The rates of CR, PR, SD, and PD were calculated along with their 95% confidence intervals.</p></sec><sec id="sec2dot3-vaccines-13-00117"><title>2.3. Evaluation of Regulatory T Cells</title><p>The levels of CD4+CD25+FOXP3+ regulatory T cells in the peripheral blood were measured by flow cytometry, as previously published [<xref rid="B18-vaccines-13-00117" ref-type="bibr">18</xref>]. Briefly, peripheral blood mononuclear cells (PBMCs) were collected, washed, and incubated with 10% normal mouse serum in PBS. The cells were then aliquoted and stained with appropriate conjugated monoclonal antibodies at 4 &#x000b0;C in the dark. The antibodies used included human CD3, CD4, CD8, CD14, CD19, CD25, CD28, CD56, CD45RA, CD45RO, and appropriate isotype controls (all antibodies purchased from BD PharMingen, San Diego, CA, USA). Stained cells were then acquired with an FACS Canto flow cytometer (BD Bioscience, San Jose, CA, USA) and analyzed with FlowJo software (version 9).</p></sec><sec id="sec2dot4-vaccines-13-00117"><title>2.4. Evaluation of Anti-Diphtheria Toxin Antibodies</title><p>Firstly, 96-well plates (Falcon MicroTest 111; Becton Dickinson, Oxnard, CA, USA) were coated with 1 pg of diphtheria toxin antigen (List Biological Laboratories, Campbell, CA, USA) per well and diluted in 50 &#x000b5;L of phosphate-buffered saline (PBS). The plates were incubated for 16 h at 4 &#x000b0;C [<xref rid="B19-vaccines-13-00117" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00117" ref-type="bibr">20</xref>]. Following this incubation, the plates were blocked for 1 h with 100 &#x000b5;L of a gelatin solution containing 0.05% Tween 20 in PBS (PBS-Tween). After blocking, the plates were rinsed three times with PBS-Tween. Next, eight serial five-fold dilutions of each serum sample (100 &#x000b5;L per well) were added to the coated plates and incubated for 1 h at room temperature. Afterward, 100 &#x000b5;L of protein A-alkaline phosphatase (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA) diluted in PBS-Tween was added to each well, followed by another 1 h of incubation at room temperature. The plates were rinsed three times with PBS-Tween and twice with PBS. Finally, 100 &#x000b5;L of substrate solution (pNPP; Kirkegaard and Perry, Gaithersburg, MD, USA) was added to each well, and the plates were incubated for 10 min. After incubation, the plates were washed again and developed as previously described [<xref rid="B21-vaccines-13-00117" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00117" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-13-00117" ref-type="bibr">23</xref>]. Diphtheria toxin-specific IgG antibodies at each time point are reported in mg/mL.</p></sec><sec id="sec2dot5-vaccines-13-00117"><title>2.5. Statistical Methods</title><p>The confidence interval of the response rate was computed by the Clopper&#x02013;Pearson exact method. For calculating the overall change in Tregs after treatment, we selected the maximal percentage of Tregs achieved post-denileukin diftitox for each individual and compared this to that individual&#x02019;s baseline Treg percentage (maximal post-denileukin diftitox Treg percentage &#x02212; baseline Treg percentage = maximal Treg percentage change). These two variables, maximal Treg percentage and baseline Treg percentage, were then compiled from all evaluable patients and compared using an exact binomial probability test. The association between the change in peripheral Treg level and the clinical response was evaluated using Cox proportional hazard (coxph) modeling. Differences in median anti-diphtheria toxin IgG antibody levels between baseline and post-denileukin diftitox treatment were assessed using a two-tailed Wilcoxon matched-pairs rank. All statistical analyses were performed using GraphPad Prism 7.01 (GraphPad Software, Inc., San Diego, CA, USA) or Microsoft Office Excel 2013 (Microsoft Corporation, Redmond, WA, USA). For comparisons involving more than three groups, two-way ANOVA followed by Bonferroni&#x02019;s post-test was used when two variables were present. <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered statistically significant in all analyses.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00117"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00117"><title>3.1. Patient Characteristics</title><p>Fifteen female patients with advanced, refractory breast cancer were enrolled in the study. Each received at least one cycle of denileukin diftitox (administered 18 mcg/kg/day on days 1&#x02013;5 of a 21-day cycle,). <xref rid="vaccines-13-00117-t001" ref-type="table">Table 1</xref> presents the patients&#x02019; demographic and baseline tumor characteristics. Ten of the fifteen enrolled patients (67%) had received four or more prior lines of systemic therapy in the metastatic setting.</p></sec><sec id="sec3dot2-vaccines-13-00117"><title>3.2. Feasibility and Toxicity of Administering Denileukin Diftitox for Treatment Refractory Breast Cancer</title><p>Of the fifteen patients enrolled in the study, four completed all six planned cycles of denileukin diftitox (<xref rid="vaccines-13-00117-f001" ref-type="fig">Figure 1</xref>). One patient completed four cycles, and another completed three cycles. Additionally, five patients completed two cycles of therapy, while four patients completed only one cycle of therapy. Of the 11 patients who did not receive all planned denileukin diftitox infusions, two discontinued the study due to toxicity, and nine stopped treatment due to disease progression. Blood samples for immune analysis were available from both the baseline and post-denileukin diftitox therapy time points in ten patients (67%).</p><p>Eleven patients reported at least one grade 3 adverse event. Of the toxicities that were deemed at least possibly related to denileukin diftitox therapy, 8% were grade 3 (<xref rid="vaccines-13-00117-t002" ref-type="table">Table 2</xref>). There was one grade 4 toxicity, lymphopenia; this toxicity was felt to be related to the study treatment and resolved within one week. The overall most common treatment-related adverse events, regardless of grade, included fatigue, hypoalbuminemia, elevated liver functions, electrolyte imbalances, and acute vascular leak (<xref rid="vaccines-13-00117-t002" ref-type="table">Table 2</xref>). A complete list of the adverse events can be found in <xref rid="app1-vaccines-13-00117" ref-type="app">Supplemental Table S1</xref>. Two patients (13%) discontinued the study due to study-related toxicities, which included either profound fatigue and weakness or persistent thrombocytopenia. Additionally, three patients (20%) required a 25% reduction in the dose of denileukin diftitox due to the toxicities of nausea, vomiting, fatigue, and diarrhea.</p></sec><sec id="sec3dot3-vaccines-13-00117"><title>3.3. Clinical Response to Denileukin Diftitox Therapy in Advanced Breast Cancer</title><p>Patients received anywhere from one to a maximum of six cycles of therapy. The best clinical response observed was stable disease in four patients (27%, 95% Clopper&#x02013;Pearson CI [0.08, 0.55]), with a median duration of 13 months (ranging from 4 to 22 months). Notably, three of these four patients with stable disease had metastatic triple-negative breast cancer (TNBC). No patients achieved a complete or partial response. Nine patients (60%) discontinued therapy due to progressive disease.</p></sec><sec id="sec3dot4-vaccines-13-00117"><title>3.4. Denileukin Diftitox Therapy Modulated Peripheral Blood FOXP3+ T Cells</title><p>Six of the fifteen (40%) evaluable patients achieved a <inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>&#x02265;</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>25% reduction in their peripheral blood CD4+CD25+FOXP3+ T cells following treatment. The mean reduction in FOXP3+ T cells in these six patients was 56.0% &#x000b1; 10.96%. Most of these patients (five out of six) experienced this reduction after completing two cycles of therapy, with the remaining patient showing a 25% reduction after four cycles. Three of the four patients with stable disease showed a &#x0003e;25% decrease in Tregs with denileukin diftitox treatment. Three of the six patients with progressive disease and post-treatment Treg levels showed a &#x0003e;25% decrease in Tregs.</p><p>In the combined analysis of all evaluable patients with baseline and post-treatment data, there was no significant difference in the levels of CD4+CD25+FOXP3+ T cells when comparing the baseline to the maximal observed Treg levels (either decrease or increase) after denileukin diftitox therapy (<italic toggle="yes">p</italic> = 0.10, one-sided) (<xref rid="vaccines-13-00117-f002" ref-type="fig">Figure 2</xref>A).</p></sec><sec id="sec3dot5-vaccines-13-00117"><title>3.5. Denileukin Diftitox Therapy Induced Anti-Diphtheria Toxin Antibodies</title><p>Among the evaluable patients, there was a significant increase in the levels of IgG anti-diphtheria toxin antibodies at week 6 compared to baseline, <italic toggle="yes">p</italic> &#x0003c; 0.005 (<xref rid="vaccines-13-00117-f002" ref-type="fig">Figure 2</xref>B). Notably, 100% of the patients (9 out of 9) who were assessed at both baseline and week 6 (after two cycles of denileukin diftitox) showed an increase in anti-diphtheria toxin IgG by week 6. </p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00117"><title>4. Discussion</title><p>Regulatory T cells (Tregs), a subset of CD4+ helper T cells, play a critical role in modulating immune responses within the tumor microenvironment by producing cytokines that suppress the proliferation of effector CD8+ T cells [<xref rid="B24-vaccines-13-00117" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00117" ref-type="bibr">25</xref>]. In both pre-invasive and invasive breast cancers, Tregs are significantly elevated compared to matched normal tissue (<italic toggle="yes">p</italic> &#x0003c; 0.05) [<xref rid="B26-vaccines-13-00117" ref-type="bibr">26</xref>]. In contrast, higher levels of intratumoral CD8+ T-cells are associated with improved breast cancer-specific survival (HR 0.55 95 % CI, 0.39 to 0.78 <italic toggle="yes">p</italic>&#x02009; = &#x02009;0.001) [<xref rid="B7-vaccines-13-00117" ref-type="bibr">7</xref>], while the presence of intratumoral Tregs is associated with a worse prognosis across all breast cancer subtypes [<xref rid="B8-vaccines-13-00117" ref-type="bibr">8</xref>]. In the adjuvant breast cancer setting, elevated Treg levels are linked to shorter disease-free survival (DFS) (HR = 3.13, 95% CI = 1.23 to 7.89) and overall survival (OS) (HR = 7.69, 95% CI = 3.43 to 17.23) [<xref rid="B27-vaccines-13-00117" ref-type="bibr">27</xref>]. Similarly, in metastatic breast cancer, progression-free survival (PFS) inversely correlates with the number of peripheral blood Tregs (AUC = 0.970, <italic toggle="yes">p</italic> = 0.004) [<xref rid="B28-vaccines-13-00117" ref-type="bibr">28</xref>].</p><p>Given the role Tregs play in inhibiting effector T cells and suppressing anti-tumor immunity, multiple agents with anti-Treg activity have been evaluated across different tumor types, including cytotoxic agents like cyclophosphamide [<xref rid="B29-vaccines-13-00117" ref-type="bibr">29</xref>] and immune interventions such as anti-CTLA-4 antibodies [<xref rid="B30-vaccines-13-00117" ref-type="bibr">30</xref>]. However, the outcomes of these systemic approaches have been mixed. In this Phase II study, treatment with denileukin diftitox led to stable disease in a subset of patients, but did not result in any partial or complete responses. Additionally, denileukin diftitox modulated Treg levels, but only in a minority of patients.</p><p>Previous clinical trials of denileukin diftitox in non-hematologic malignancies have also investigated its impact on peripheral blood Tregs, yielding conflicting results. Treg reductions have been reported in renal cell carcinoma (26&#x02013;76% reduction) [<xref rid="B16-vaccines-13-00117" ref-type="bibr">16</xref>], ovarian cancer (significant reduction of mean Treg levels, <italic toggle="yes">p</italic> = 0.025) [<xref rid="B14-vaccines-13-00117" ref-type="bibr">14</xref>], colorectal cancer (Treg reduction in the majority of evaluable patients) [<xref rid="B31-vaccines-13-00117" ref-type="bibr">31</xref>], and melanoma (Treg reduction in all treated patients) [<xref rid="B15-vaccines-13-00117" ref-type="bibr">15</xref>]. However, two other melanoma studies have reported no significant decrease in Treg levels after denileukin diftitox treatment [<xref rid="B32-vaccines-13-00117" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00117" ref-type="bibr">33</xref>]. No prior studies have specifically evaluated the use of denileukin diftitox in metastatic breast cancer. To date, there has been no definitive evidence of clinical benefit associated with Treg depletion in denileukin diftitox-treated patients [<xref rid="B31-vaccines-13-00117" ref-type="bibr">31</xref>,<xref rid="B33-vaccines-13-00117" ref-type="bibr">33</xref>].</p><p>Several factors may explain the low clinical and Treg response rate observed in our study. One possibility is the presence of neutralizing antibodies against denileukin diftitox. Previous studies in patients with cutaneous T-cell lymphoma (CTCL) [<xref rid="B13-vaccines-13-00117" ref-type="bibr">13</xref>,<xref rid="B34-vaccines-13-00117" ref-type="bibr">34</xref>], chronic lymphocytic leukemia (CLL) [<xref rid="B35-vaccines-13-00117" ref-type="bibr">35</xref>], CD25-expressing lymphomas [<xref rid="B36-vaccines-13-00117" ref-type="bibr">36</xref>], and melanoma [<xref rid="B33-vaccines-13-00117" ref-type="bibr">33</xref>] have identified anti-diphtheria toxin antibodies in a modest number of patients at baseline, with most patients developing these antibodies after treatment [<xref rid="B13-vaccines-13-00117" ref-type="bibr">13</xref>,<xref rid="B33-vaccines-13-00117" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00117" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00117" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00117" ref-type="bibr">36</xref>]. Another potential factor is the dosing schema used in this study. Clinical trials with shorter dosing schedules and lower doses of denileukin diftitox demonstrated statistically significant suppression of CD4+CD25+ Tregs [<xref rid="B14-vaccines-13-00117" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00117" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-13-00117" ref-type="bibr">16</xref>,<xref rid="B31-vaccines-13-00117" ref-type="bibr">31</xref>]. These findings suggest that a truncated administration schedule and lower dosage of denileukin diftitox per cycle might be more effective in reducing circulating Tregs while also minimizing toxicity, as compared to prolonged treatment at higher doses.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00117"><title>5. Conclusions</title><p>Denileukin diftitox therapy in patients with advanced breast cancer led to modest modulation of circulating Tregs, but also resulted in moderate toxicity within this cohort. The majority of patients experienced disease progression, with only a minority achieving disease stabilization. To potentially improve outcomes, future studies should explore alternative dosing schedules that may offer more consistent Treg depletion and more favorable toxicity profiles.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank the patients and their families for their participation in this trial. We wish to thank James Waisman for his oversight of this trial at the City of Hope Cancer Center in Duarte, CA. We wish to thank Corazon dela Rosa for her work performing correlative studies in support of the immune analysis for trial. Denileukin diftitox (ONTAK) was supplied by the Eisai Company. We wish to thank Shaveta Vinayak and Natasha Hunter for their work editing the manuscript. </p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00117"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020117/s1">https://www.mdpi.com/article/10.3390/vaccines13020117/s1</uri>, Table S1: Detailed adverse events.</p><supplementary-material id="vaccines-13-00117-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00117-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>L.G.S. and M.L.D. contributed to the design of this trial. L.G.S., M.L.D., and A.L.C. oversaw the conduct of this trial. D.H., J.S.C., and R.B. contributed substantially to patient recruitment. W.R.G.III, L.G.S., J.Y.D., J.R., M.S., H.L., and M.L.D. contributed to data collection. Y.D., J.Y.D., J.R., M.S., and H.L. contributed to data analysis and data interpretation. W.R.G.III and M.L.D. contributed to the writing of the report. W.R.G.III, J.R., J.S.C., and M.S. contributed to the production of the figures. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of University of Washington/Fred Hutch Cancer Center Consortium (IR# 6308 and Initial IRB Approval Date: 21 September 2005).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Author Hailing Lu was employed by the company Seattle Genetics (Pfizer). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00117"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cimino-Mathews</surname><given-names>A.</given-names></name>
<name><surname>Foote</surname><given-names>J.B.</given-names></name>
<name><surname>Emens</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Immune targeting in breast cancer</article-title><source>Oncology</source><year>2015</year><volume>29</volume><fpage>375</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">25979549</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00117"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Sirtaine</surname><given-names>N.</given-names></name>
<name><surname>Piette</surname><given-names>F.</given-names></name>
<name><surname>Salgado</surname><given-names>R.</given-names></name>
<name><surname>Viale</surname><given-names>G.</given-names></name>
<name><surname>Van Eenoo</surname><given-names>F.</given-names></name>
<name><surname>Rouas</surname><given-names>G.</given-names></name>
<name><surname>Francis</surname><given-names>P.</given-names></name>
<name><surname>Crown</surname><given-names>J.P.</given-names></name>
<name><surname>Hitre</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2013</year><volume>31</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.41.0902</pub-id></element-citation></ref><ref id="B3-vaccines-13-00117"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adams</surname><given-names>S.</given-names></name>
<name><surname>Gray</surname><given-names>R.J.</given-names></name>
<name><surname>Demaria</surname><given-names>S.</given-names></name>
<name><surname>Goldstein</surname><given-names>L.</given-names></name>
<name><surname>Perez</surname><given-names>E.A.</given-names></name>
<name><surname>Shulman</surname><given-names>L.N.</given-names></name>
<name><surname>Martino</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Jones</surname><given-names>V.E.</given-names></name>
<name><surname>Saphner</surname><given-names>T.J.</given-names></name>
<etal/>
</person-group><article-title>Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>2959</fpage><lpage>2966</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.55.0491</pub-id><pub-id pub-id-type="pmid">25071121</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00117"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loi</surname><given-names>S.</given-names></name>
<name><surname>Michiels</surname><given-names>S.</given-names></name>
<name><surname>Salgado</surname><given-names>R.</given-names></name>
<name><surname>Sirtaine</surname><given-names>N.</given-names></name>
<name><surname>Jose</surname><given-names>V.</given-names></name>
<name><surname>Fumagalli</surname><given-names>D.</given-names></name>
<name><surname>Kellokumpu-Lehtinen</surname><given-names>P.L.</given-names></name>
<name><surname>Bono</surname><given-names>P.</given-names></name>
<name><surname>Kataja</surname><given-names>V.</given-names></name>
<name><surname>Desmedt</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial</article-title><source>Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.</source><year>2014</year><volume>25</volume><fpage>1544</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu112</pub-id><pub-id pub-id-type="pmid">24608200</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00117"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fridman</surname><given-names>W.H.</given-names></name>
<name><surname>Zitvogel</surname><given-names>L.</given-names></name>
<name><surname>Sautes-Fridman</surname><given-names>C.</given-names></name>
<name><surname>Kroemer</surname><given-names>G.</given-names></name>
</person-group><article-title>The immune contexture in cancer prognosis and treatment</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>717</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.101</pub-id><pub-id pub-id-type="pmid">28741618</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00117"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galon</surname><given-names>J.</given-names></name>
<name><surname>Costes</surname><given-names>A.</given-names></name>
<name><surname>Sanchez-Cabo</surname><given-names>F.</given-names></name>
<name><surname>Kirilovsky</surname><given-names>A.</given-names></name>
<name><surname>Mlecnik</surname><given-names>B.</given-names></name>
<name><surname>Lagorce-Pages</surname><given-names>C.</given-names></name>
<name><surname>Tosolini</surname><given-names>M.</given-names></name>
<name><surname>Camus</surname><given-names>M.</given-names></name>
<name><surname>Berger</surname><given-names>A.</given-names></name>
<name><surname>Wind</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id><pub-id pub-id-type="pmid">17008531</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00117"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahmoud</surname><given-names>S.M.</given-names></name>
<name><surname>Paish</surname><given-names>E.C.</given-names></name>
<name><surname>Powe</surname><given-names>D.G.</given-names></name>
<name><surname>Macmillan</surname><given-names>R.D.</given-names></name>
<name><surname>Grainge</surname><given-names>M.J.</given-names></name>
<name><surname>Lee</surname><given-names>A.H.</given-names></name>
<name><surname>Ellis</surname><given-names>I.O.</given-names></name>
<name><surname>Green</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2011</year><volume>29</volume><fpage>1949</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.5037</pub-id><pub-id pub-id-type="pmid">21483002</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00117"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shang</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>S.J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
</person-group><article-title>Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: A systematic review and meta-analysis</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><elocation-id>15179</elocation-id><pub-id pub-id-type="doi">10.1038/srep15179</pub-id><pub-id pub-id-type="pmid">26462617</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00117"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stanton</surname><given-names>S.E.</given-names></name>
<name><surname>Adams</surname><given-names>S.</given-names></name>
<name><surname>Disis</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review</article-title><source>J. Am. Med. Assoc. Oncol.</source><year>2016</year><volume>2</volume><fpage>1354</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.1061</pub-id></element-citation></ref><ref id="B10-vaccines-13-00117"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zitvogel</surname><given-names>L.</given-names></name>
<name><surname>Galluzzi</surname><given-names>L.</given-names></name>
<name><surname>Kepp</surname><given-names>O.</given-names></name>
<name><surname>Smyth</surname><given-names>M.J.</given-names></name>
<name><surname>Kroemer</surname><given-names>G.</given-names></name>
</person-group><article-title>Type I interferons in anticancer immunity</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nri3845</pub-id><pub-id pub-id-type="pmid">26027717</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00117"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bates</surname><given-names>G.J.</given-names></name>
<name><surname>Fox</surname><given-names>S.B.</given-names></name>
<name><surname>Han</surname><given-names>C.</given-names></name>
<name><surname>Leek</surname><given-names>R.D.</given-names></name>
<name><surname>Garcia</surname><given-names>J.F.</given-names></name>
<name><surname>Harris</surname><given-names>A.L.</given-names></name>
<name><surname>Banham</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2006</year><volume>24</volume><fpage>5373</fpage><lpage>5380</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.05.9584</pub-id><pub-id pub-id-type="pmid">17135638</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00117"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Re</surname><given-names>G.G.</given-names></name>
<name><surname>Waters</surname><given-names>C.</given-names></name>
<name><surname>Poisson</surname><given-names>L.</given-names></name>
<name><surname>Willingham</surname><given-names>M.C.</given-names></name>
<name><surname>Sugamura</surname><given-names>K.</given-names></name>
<name><surname>Frankel</surname><given-names>A.E.</given-names></name>
</person-group><article-title>Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells</article-title><source>Cancer Res.</source><year>1996</year><volume>56</volume><fpage>2590</fpage><lpage>2595</lpage><pub-id pub-id-type="pmid">8653702</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00117"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foss</surname><given-names>F.M.</given-names></name>
<name><surname>Kim</surname><given-names>Y.H.</given-names></name>
<name><surname>Prince</surname><given-names>H.M.</given-names></name>
<name><surname>Kuzel</surname><given-names>T.M.</given-names></name>
<name><surname>Yannakou</surname><given-names>C.K.</given-names></name>
<name><surname>Ooi</surname><given-names>C.E.</given-names></name>
<name><surname>Xing</surname><given-names>D.</given-names></name>
<name><surname>Sauter</surname><given-names>N.</given-names></name>
<name><surname>Singh</surname><given-names>P.</given-names></name>
<name><surname>Czuczman</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302</article-title><source>Blood</source><year>2022</year><volume>140</volume><issue>(Suppl. S1)</issue><fpage>1491</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1182/blood-2022-166916</pub-id></element-citation></ref><ref id="B14-vaccines-13-00117"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnett</surname><given-names>B.</given-names></name>
<name><surname>Kryczek</surname><given-names>I.</given-names></name>
<name><surname>Cheng</surname><given-names>P.</given-names></name>
<name><surname>Zou</surname><given-names>W.</given-names></name>
<name><surname>Curiel</surname><given-names>T.J.</given-names></name>
</person-group><article-title>Regulatory T cells in ovarian cancer: Biology and therapeutic potential</article-title><source>Am. J. Reprod. Immunol.</source><year>2005</year><volume>54</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0897.2005.00330.x</pub-id><pub-id pub-id-type="pmid">16305662</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00117"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahnke</surname><given-names>K.</given-names></name>
<name><surname>Schonfeld</surname><given-names>K.</given-names></name>
<name><surname>Fondel</surname><given-names>S.</given-names></name>
<name><surname>Ring</surname><given-names>S.</given-names></name>
<name><surname>Karakhanova</surname><given-names>S.</given-names></name>
<name><surname>Wiedemeyer</surname><given-names>K.</given-names></name>
<name><surname>Bedke</surname><given-names>T.</given-names></name>
<name><surname>Johnson</surname><given-names>T.S.</given-names></name>
<name><surname>Storn</surname><given-names>V.</given-names></name>
<name><surname>Schallenberg</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro</article-title><source>Int. J. Cancer</source><year>2007</year><volume>120</volume><fpage>2723</fpage><lpage>2733</lpage><pub-id pub-id-type="doi">10.1002/ijc.22617</pub-id><pub-id pub-id-type="pmid">17315189</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00117"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dannull</surname><given-names>J.</given-names></name>
<name><surname>Su</surname><given-names>Z.</given-names></name>
<name><surname>Rizzieri</surname><given-names>D.</given-names></name>
<name><surname>Yang</surname><given-names>B.K.</given-names></name>
<name><surname>Coleman</surname><given-names>D.</given-names></name>
<name><surname>Yancey</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
<name><surname>Dahm</surname><given-names>P.</given-names></name>
<name><surname>Chao</surname><given-names>N.</given-names></name>
<name><surname>Gilboa</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells</article-title><source>J. Clin. Investig.</source><year>2005</year><volume>115</volume><fpage>3623</fpage><lpage>3633</lpage><pub-id pub-id-type="doi">10.1172/JCI25947</pub-id><pub-id pub-id-type="pmid">16308572</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00117"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knutson</surname><given-names>K.L.</given-names></name>
<name><surname>Dang</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Lukas</surname><given-names>J.</given-names></name>
<name><surname>Almand</surname><given-names>B.</given-names></name>
<name><surname>Gad</surname><given-names>E.</given-names></name>
<name><surname>Azeke</surname><given-names>E.</given-names></name>
<name><surname>Disis</surname><given-names>M.L.</given-names></name>
</person-group><article-title>IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice</article-title><source>J. Immunol.</source><year>2006</year><volume>177</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.1.84</pub-id><pub-id pub-id-type="pmid">16785502</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00117"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Disis</surname><given-names>M.L.</given-names></name>
<name><surname>Dang</surname><given-names>Y.</given-names></name>
<name><surname>Coveler</surname><given-names>A.L.</given-names></name>
<name><surname>Marzbani</surname><given-names>E.</given-names></name>
<name><surname>Kou</surname><given-names>Z.C.</given-names></name>
<name><surname>Childs</surname><given-names>J.S.</given-names></name>
<name><surname>Fintak</surname><given-names>P.</given-names></name>
<name><surname>Higgins</surname><given-names>D.M.</given-names></name>
<name><surname>Reichow</surname><given-names>J.</given-names></name>
<name><surname>Waisman</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers</article-title><source>Cancer Immunol. Immunother. CII</source><year>2014</year><volume>63</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/s00262-013-1489-4</pub-id><pub-id pub-id-type="pmid">24162107</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00117"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murphy</surname><given-names>J.R.</given-names></name>
<name><surname>Bacha</surname><given-names>P.</given-names></name>
<name><surname>Teng</surname><given-names>M.</given-names></name>
</person-group><article-title>Determination of Corynebacterium diphtheriae toxigenicity by a colorimetric tissue culture assay</article-title><source>J. Clin. Microbiol.</source><year>1978</year><volume>7</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1128/jcm.7.1.91-96.1978</pub-id><pub-id pub-id-type="pmid">415068</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00117"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zucker</surname><given-names>D.R.</given-names></name>
<name><surname>Murphy</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Monoclonal antibody analysis of diphtheria toxin--I. Localization of epitopes and neutralization of cytotoxicity</article-title><source>Mol. Immunol.</source><year>1984</year><volume>21</volume><fpage>785</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/0161-5890(84)90165-2</pub-id><pub-id pub-id-type="pmid">6207425</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00117"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodell</surname><given-names>V.</given-names></name>
<name><surname>Disis</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity</article-title><source>J. Immunol. Methods</source><year>2005</year><volume>299</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2005.02.002</pub-id><pub-id pub-id-type="pmid">15914197</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00117"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Disis</surname><given-names>M.L.</given-names></name>
<name><surname>Schiffman</surname><given-names>K.</given-names></name>
<name><surname>Guthrie</surname><given-names>K.</given-names></name>
<name><surname>Salazar</surname><given-names>L.G.</given-names></name>
<name><surname>Knutson</surname><given-names>K.L.</given-names></name>
<name><surname>Goodell</surname><given-names>V.</given-names></name>
<name><surname>dela Rosa</surname><given-names>C.</given-names></name>
<name><surname>Cheever</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2004</year><volume>22</volume><fpage>1916</fpage><lpage>1925</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.09.005</pub-id></element-citation></ref><ref id="B23-vaccines-13-00117"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>LeMaistre</surname><given-names>C.F.</given-names></name>
<name><surname>Meneghetti</surname><given-names>C.</given-names></name>
<name><surname>Rosenblum</surname><given-names>M.</given-names></name>
<name><surname>Reuben</surname><given-names>J.</given-names></name>
<name><surname>Parker</surname><given-names>K.</given-names></name>
<name><surname>Shaw</surname><given-names>J.</given-names></name>
<name><surname>Deisseroth</surname><given-names>A.</given-names></name>
<name><surname>Woodworth</surname><given-names>T.</given-names></name>
<name><surname>Parkinson</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor</article-title><source>Blood</source><year>1992</year><volume>79</volume><fpage>2547</fpage><lpage>2554</lpage><pub-id pub-id-type="doi">10.1182/blood.V79.10.2547.bloodjournal79102547</pub-id><pub-id pub-id-type="pmid">1586707</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00117"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thornton</surname><given-names>A.M.</given-names></name>
<name><surname>Shevach</surname><given-names>E.M.</given-names></name>
</person-group><article-title>CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production</article-title><source>J. Exp. Med.</source><year>1998</year><volume>188</volume><fpage>287</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1084/jem.188.2.287</pub-id><pub-id pub-id-type="pmid">9670041</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00117"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ng</surname><given-names>W.F.</given-names></name>
<name><surname>Duggan</surname><given-names>P.J.</given-names></name>
<name><surname>Ponchel</surname><given-names>F.</given-names></name>
<name><surname>Matarese</surname><given-names>G.</given-names></name>
<name><surname>Lombardi</surname><given-names>G.</given-names></name>
<name><surname>Edwards</surname><given-names>A.D.</given-names></name>
<name><surname>Isaacs</surname><given-names>J.D.</given-names></name>
<name><surname>Lechler</surname><given-names>R.I.</given-names></name>
</person-group><article-title>Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>2736</fpage><lpage>2744</lpage><pub-id pub-id-type="doi">10.1182/blood.V98.9.2736</pub-id><pub-id pub-id-type="pmid">11675346</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00117"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohara</surname><given-names>M.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>Y.</given-names></name>
<name><surname>Matsuura</surname><given-names>K.</given-names></name>
<name><surname>Murakami</surname><given-names>S.</given-names></name>
<name><surname>Arihiro</surname><given-names>K.</given-names></name>
<name><surname>Okada</surname><given-names>M.</given-names></name>
</person-group><article-title>Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer</article-title><source>Cancer Immunol. Immunother. CII</source><year>2009</year><volume>58</volume><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0570-x</pub-id><pub-id pub-id-type="pmid">18685848</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00117"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bense</surname><given-names>R.D.</given-names></name>
<name><surname>Sotiriou</surname><given-names>C.</given-names></name>
<name><surname>Piccart-Gebhart</surname><given-names>M.J.</given-names></name>
<name><surname>Haanen</surname><given-names>J.B.</given-names></name>
<name><surname>van Vugt</surname><given-names>M.A.</given-names></name>
<name><surname>de Vries</surname><given-names>E.G.</given-names></name>
<name><surname>Schroder</surname><given-names>C.P.</given-names></name>
<name><surname>Fehrmann</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer</article-title><source>J. Natl. Cancer Inst.</source><year>2017</year><volume>109</volume><fpage>djw192</fpage><pub-id pub-id-type="doi">10.1093/jnci/djw192</pub-id><pub-id pub-id-type="pmid">27737921</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00117"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petricevic</surname><given-names>B.</given-names></name>
<name><surname>Laengle</surname><given-names>J.</given-names></name>
<name><surname>Singer</surname><given-names>J.</given-names></name>
<name><surname>Sachet</surname><given-names>M.</given-names></name>
<name><surname>Fazekas</surname><given-names>J.</given-names></name>
<name><surname>Steger</surname><given-names>G.</given-names></name>
<name><surname>Bartsch</surname><given-names>R.</given-names></name>
<name><surname>Jensen-Jarolim</surname><given-names>E.</given-names></name>
<name><surname>Bergmann</surname><given-names>M.</given-names></name>
</person-group><article-title>Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients</article-title><source>J. Transl. Med.</source><year>2013</year><volume>11</volume><fpage>307</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-11-307</pub-id><pub-id pub-id-type="pmid">24330813</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00117"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Leatherman</surname><given-names>J.M.</given-names></name>
<name><surname>Sunay</surname><given-names>M.E.</given-names></name>
<name><surname>Emens</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Abstract 4749: Cyclophosphamide induces dose dependent apoptosis of CD4+FoxP3+ regulatory T cells relative to CD4+FoxP3- effector T cells in breast cancer patients</article-title><source>Cancer Res.</source><year>2013</year><volume>73</volume><fpage>4749</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2013-4749</pub-id></element-citation></ref><ref id="B30-vaccines-13-00117"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Syn</surname><given-names>N.L.</given-names></name>
<name><surname>Teng</surname><given-names>M.W.L.</given-names></name>
<name><surname>Mok</surname><given-names>T.S.K.</given-names></name>
<name><surname>Soo</surname><given-names>R.A.</given-names></name>
</person-group><article-title>De-novo and acquired resistance to immune checkpoint targeting</article-title><source>Lancet Oncol.</source><year>2017</year><volume>18</volume><fpage>e731</fpage><lpage>e741</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(17)30607-1</pub-id><pub-id pub-id-type="pmid">29208439</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00117"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morse</surname><given-names>M.A.</given-names></name>
<name><surname>Hobeika</surname><given-names>A.C.</given-names></name>
<name><surname>Osada</surname><given-names>T.</given-names></name>
<name><surname>Serra</surname><given-names>D.</given-names></name>
<name><surname>Niedzwiecki</surname><given-names>D.</given-names></name>
<name><surname>Lyerly</surname><given-names>H.K.</given-names></name>
<name><surname>Clay</surname><given-names>T.M.</given-names></name>
</person-group><article-title>Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-01-135319</pub-id><pub-id pub-id-type="pmid">18519811</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00117"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Vries</surname><given-names>I.J.</given-names></name>
<name><surname>Castelli</surname><given-names>C.</given-names></name>
<name><surname>Huygens</surname><given-names>C.</given-names></name>
<name><surname>Jacobs</surname><given-names>J.F.</given-names></name>
<name><surname>Stockis</surname><given-names>J.</given-names></name>
<name><surname>Schuler-Thurner</surname><given-names>B.</given-names></name>
<name><surname>Adema</surname><given-names>G.J.</given-names></name>
<name><surname>Punt</surname><given-names>C.J.</given-names></name>
<name><surname>Rivoltini</surname><given-names>L.</given-names></name>
<name><surname>Schuler</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and po-tentially Treg-depleting agents</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>841</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2227</pub-id><pub-id pub-id-type="pmid">21177412</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00117"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Attia</surname><given-names>P.</given-names></name>
<name><surname>Maker</surname><given-names>A.V.</given-names></name>
<name><surname>Haworth</surname><given-names>L.R.</given-names></name>
<name><surname>Rogers-Freezer</surname><given-names>L.</given-names></name>
<name><surname>Rosenberg</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma</article-title><source>J. Immunother.</source><year>2005</year><volume>28</volume><fpage>582</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1097/01.cji.0000175468.19742.10</pub-id><pub-id pub-id-type="pmid">16224276</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00117"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Foss</surname><given-names>F.M.</given-names></name>
<name><surname>Bacha</surname><given-names>P.</given-names></name>
<name><surname>Osann</surname><given-names>K.E.</given-names></name>
<name><surname>Demierre</surname><given-names>M.F.</given-names></name>
<name><surname>Bell</surname><given-names>T.</given-names></name>
<name><surname>Kuzel</surname><given-names>T.</given-names></name>
</person-group><article-title>Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication</article-title><source>Clin. Lymphoma</source><year>2001</year><volume>1</volume><fpage>298</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.3816/CLM.2001.n.005</pub-id><pub-id pub-id-type="pmid">11707845</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00117"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frankel</surname><given-names>A.E.</given-names></name>
<name><surname>Fleming</surname><given-names>D.R.</given-names></name>
<name><surname>Hall</surname><given-names>P.D.</given-names></name>
<name><surname>Powell</surname><given-names>B.L.</given-names></name>
<name><surname>Black</surname><given-names>J.H.</given-names></name>
<name><surname>Leftwich</surname><given-names>C.</given-names></name>
<name><surname>Gartenhaus</surname><given-names>R.</given-names></name>
</person-group><article-title>A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2003</year><volume>9</volume><fpage>3555</fpage><lpage>3561</lpage></element-citation></ref><ref id="B36-vaccines-13-00117"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>LeMaistre</surname><given-names>C.F.</given-names></name>
<name><surname>Saleh</surname><given-names>M.N.</given-names></name>
<name><surname>Kuzel</surname><given-names>T.M.</given-names></name>
<name><surname>Foss</surname><given-names>F.</given-names></name>
<name><surname>Platanias</surname><given-names>L.C.</given-names></name>
<name><surname>Schwartz</surname><given-names>G.</given-names></name>
<name><surname>Ratain</surname><given-names>M.</given-names></name>
<name><surname>Rook</surname><given-names>A.</given-names></name>
<name><surname>Freytes</surname><given-names>C.O.</given-names></name>
<name><surname>Craig</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2</article-title><source>Blood</source><year>1998</year><volume>91</volume><fpage>399</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">9427692</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00117-f001"><label>Figure 1</label><caption><p>Patient flow chart.</p></caption><graphic xlink:href="vaccines-13-00117-g001" position="float"/></fig><fig position="float" id="vaccines-13-00117-f002"><label>Figure 2</label><caption><p>Denileukin diftitox (DD) therapy modulated peripheral blood FOXP3+ T cells and induced anti-diphtheria toxin (DT) antibodies. (<bold>A</bold>) Flow analysis evaluation of the % of peripheral blood CD4+ cells positive for FoxP3+ at the following study time points: baseline (week 0), week 6, week 12, week 18, and week 23. Five patients were evaluable with blood draws beyond week 6. Decrease in Tregs (Blue), increase in Tregs (Purple) Each line corresponds to an individual patient. (<bold>B</bold>) ELISA analysis of the change in diphtheria toxin (DT)-specific antibodies between baseline and post-treatment. Each line corresponds to an individual patient, and 100% (9/9) of pts who were evaluated at week 6 (after two cycles of DD) had an increase in anti-DT IgG from baseline ** <italic toggle="yes">p</italic> &#x0003c; 0.005.</p></caption><graphic xlink:href="vaccines-13-00117-g002" position="float"/></fig><table-wrap position="float" id="vaccines-13-00117-t001"><object-id pub-id-type="pii">vaccines-13-00117-t001_Table 1</object-id><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Patients</th><th align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">Age (Median, Range)</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">58 (32&#x02013;69)</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">15</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">100</td></tr><tr><td colspan="2" align="left" valign="bottom" rowspan="1">Number of Disease Site(s)</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x02003;&#x02003;Bone, LN and soft tissue only (including skin)</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">6</td><td align="center" valign="bottom" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x02003;&#x02003;Visceral</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x02003;&#x02003;Mixed</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">Breast Cancer Subtype</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;ER and/or PR+ *</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">6</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;HER2+ (overexpressing/amplified)</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">5</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">33</td></tr><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;TNBC (ER/PR/HER2-)</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Number of Prior Anti-Estrogen </td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x02003;&#x02003;1&#x02013;2 regimens</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">5</td><td align="center" valign="bottom" rowspan="1" colspan="1">33</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02265; 3 regimens</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">5</td><td align="center" valign="bottom" rowspan="1" colspan="1">33</td></tr><tr><td colspan="2" align="left" valign="bottom" style="background:#D9D9D9" rowspan="1">Number of Prior Cytotoxic Chemotherpay</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="left" valign="bottom" style="background:#D9D9D9" rowspan="1">&#x02003;&#x02003;2&#x02013;3 regimens</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">7</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">47%</td></tr><tr><td colspan="2" align="left" valign="bottom" style="background:#D9D9D9" rowspan="1">&#x02003;&#x02003;&#x02265;4</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">8</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="left" valign="bottom" rowspan="1">Number of Prior HER2 therapies</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" rowspan="1" colspan="1">
</td></tr><tr><td colspan="2" align="left" valign="bottom" rowspan="1">&#x02003;&#x02003;1&#x02013;2</td><td align="center" valign="bottom" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" rowspan="1" colspan="1">26</td></tr><tr><td colspan="2" align="left" valign="bottom" style="background:#D9D9D9" rowspan="1">Months from Last Therapy to Enrollment</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;&#x0003c;1 month</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">8</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;2&#x02013;3 months</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">4</td><td align="center" valign="bottom" style="background:#D9D9D9" rowspan="1" colspan="1">26</td></tr><tr><td align="left" valign="bottom" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02265;4 months</td><td align="center" valign="bottom" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td><td align="center" valign="bottom" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">3</td><td align="center" valign="bottom" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>* Two patient did not have outside pathology for ER/PR/HER2 testing, but had received prior anti-estrogen therapy and had not received anit-HER2 therapy, so they were grouped in ER/PR+ subtype.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00117-t002"><object-id pub-id-type="pii">vaccines-13-00117-t002_Table 2</object-id><label>Table 2</label><caption><p>Adverse events, including AEs judged to be possibly, probably, or definitely related to treatment with ONTAK.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5" align="center" valign="bottom" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Protocol 127 Adverse Events (n = 589)</th></tr><tr><th align="center" valign="bottom" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="bottom" rowspan="1">Possibly, Probably, or Definitely Related</th><th colspan="2" align="center" valign="middle" rowspan="1">All AEs</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Most Common</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% of Related AEs</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% of All AEs</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Fatigue</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Hypoalbuminemia</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Hypokalemia</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;ALT, SGPT elevated</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">33</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Hypocalcemia</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;AST, SGOT elevated</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Acute vascular leak syndrome</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Nausea</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Constipation</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">&#x02003;&#x02003;Hyperglycemia</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="background:#D9D9D9" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AE Gradings</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;1</td><td align="center" valign="middle" rowspan="1" colspan="1">242</td><td align="center" valign="middle" rowspan="1" colspan="1">67</td><td align="center" valign="middle" rowspan="1" colspan="1">416</td><td align="center" valign="middle" rowspan="1" colspan="1">71</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;2</td><td align="center" valign="middle" rowspan="1" colspan="1">87</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">142</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;3</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x02003;4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></floats-group></article>